Category Archives: Regenerative Medicine

Gilbert, Arizona (PRWEB) July 08, 2014

The top Gilbert pain management clinic, Arizona Pain Specialists, is now offering over 25 effective back pain treatment options. The Arizona pain management center has now added regenerative medicine options along with cutting edge back pain treatments, which often provide over a year of pain relief. Call (480) 535-6722 to take advantage of the options.

Back pain affects 90% of individuals at some point. It may be disabling and prevent those affected from working, playing with one's kids or enjoying life. Arizona Pain continues to add back pain treatment options at its Gilbert location, combining both traditional and alternative therapies for optimal relief.

Board Certified pain management doctors work closely with chiropractors, acupuncturists and physical rehabilitation providers to customize treatment regimens for patients. New additions to the options include regenerative medicine treatments with stem cell procedures. These include both amniotic and bone marrow derived procedures.

Cutting edge additions to the interventional procedures include spinal cord stimulator implants and radiofrequency ablation procedures. These are excellent options for those suffering from chronic low back pain to provide much needed relief.

The Gilbert chiropractors at Arizona Pain offer revolutionary spinal decompression therapy, which is FDA cleared and effective in over 85% of patients. With all of the options available now with pain management Gilbert AZ trusts, Arizona Pain achieves over 95% success rates.

Over 50 insurance plans are accepted at the Center including PPO's, some HMO's, Medicare, Medicaid, personal injury liens, workers compensation and self pay as well. Call (480) 535-6722 for more information and scheduling.

Here is the original post:
Top Gilbert Pain Management Center, Arizona Pain Specialists, Now Offering Over 25 Nonoperative Back Pain Treatments

San Diego, California (PRWEB) July 02, 2014

Vet-Stem, Inc., the leader and pioneer in Regenerative Veterinary Medicine for over a decade, has selected Aratana Therapeutics, a fast-growing pet therapeutics company, as its commercial partner to develop regenerative medicine in the treatment of canine osteoarthritis. Vet-Stem believes that this market validation by Aratana creates the potential for additional future partnerships to develop a portfolio of regenerative medicine products for the veterinary industry. As the best-in-class pet therapeutics company, Aratana believes the development and commercialization of novel new products will permit veterinarians and pet owners to manage pets medical needs safely and effectively, resulting in longer and improved quality of life. This commitment parallels Vet-Stems evidence-based approach to harnessing the bodys regenerative ability to repair damaged tissue and improve quality of life. Aratanas focus on pain and osteoarthritis is very complementary to Vet-Stems current services and future stem cell products in development.

The initial licensing deal between Vet-Stem and Aratana is a collaboration to co-develop the first off-the-shelf stem cell product for the canine osteoarthritis market in the United States under FDA approval. Under terms of the agreement, additional markets may be developed upon mutual agreement. As many as 2/3 of dogs over 7 years old are affected by osteoarthritis, which has created the largest existing market segment in pet therapeutics. Although currently marketed products can help decrease the crippling symptoms of osteoarthritis, they are not designed to regenerate and heal the damaged tissue that is causing pain. Regenerative medicine focuses on true regeneration of damaged tissues and organs.

Robert Harman, DVM, Founder and Chief Executive Officer of Vet-Stem stated, "This initial licensing agreement builds on our foundational stem cell laboratory services by providing resources to develop the next generation of regenerative medicine products. As we complete the final stages of FDA approval of the canine osteoarthritis product with Aratana, our laboratory will continue to provide stem cell laboratory services to our veterinary clients. The extensive experience in clinical stem cell therapy for dogs, cats and horses will allow the continuous flow of FDA product development projects to bring effective and economical regenerative medicine to our industry. We believe regenerative medicine will continue to re-shape the way we approach therapy of all animal patients.

We have chosen Aratana as a commercialization partner for our canine osteoarthritis product because of their passionate commitment to novel pet therapeutics, and we look for other potential partners that are passionate about bringing novel products to market to contact us regarding partnering other products in our portfolio, states Dr. Harman.

Steven St. Peter, MD, President and Chief Executive Officer of Aratana Therapeutics, stated, We are pleased to expand our pain franchise further by adding an allogeneic, regenerative cell therapy product, which in addition to reducing the pain of osteoarthritis, has the potential to impact the progression of the disease and to promote tissue regeneration.

About Vet-Stem, Inc. Vet-Stem, Inc. is a privately held veterinary biotechnology company founded in 2002 in the leading global biotechnology and bioscience area of San Diego, California. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for horses, dogs, cats, and some exotics, Vet-Stem has established a strong brand over the last decade that is based in science and backed by industry professionals globally. In the quest to remain the flagship Regenerative Veterinary Medicine Company, Vet-Stem has contributed to 11 peer-reviewed papers including the first blinded, controlled, multicenter study of adipose-derived stem cells for chronic osteoarthritis in the canine hip joint. Vet-Stem currently holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose-derived stem cells, with over 75 patents pending. Over 10,000 animals have been treated using Vet-Stem technology, and the company is actively investigating stem cell therapy for immune-mediated and inflammatory diseases, as well as organ disease and failure. For more information about Vet-Stem and Regenerative Veterinary Medicine, visit http://www.vet-stem.com or call 858-748-2004.

More here:
Landmark Licensing Deal in Regenerative Veterinary Medicine a First as Vet-Stem Selects Aratana as Partner to ...

Tampa, FL (PRWEB) June 27, 2014

Furthering its goal to restore quality of life to patients with little or no hope of medical improvement, Regenerative Medicine Solutions (RMS) announced today that it has entered into an agreement to acquire Advanced Healthcare Partners (AHP). The strategy behind the business move was the realignment of resources, and the innovative use of stem cells to treat an array of medical conditions under one roof. AHP was a leading healthcare management and consulting company, which owned and operated the Lung Institute.

We are now ready to continue growing the Lung Institute to be the world leader in the care of patients suffering from lung disease by providing the best option for their treatment, said Jimmy St. Louis, Chief Executive Officer of RMS. In order to accomplish this mission, we needed to combine all of our teammates and resources together to focus on one company and one mission, RMS.

As a leader in regenerative medicine, the Lung Institute utilizes stem cells from the patients own body to treat lung disease. These autologous cells work to promote the repair and regeneration of previously damaged lung tissue. RMS is a global provider of stem cell therapy for medical conditions in areas of the body other than the lung.

All AHP and Lung Institute 31 employees are now considered employees of RMS, added St. Louis. With everyone together as one cohesive team, we have tripled our number. We are one team, with one goal: utilization of regenerative medicine to improve the quality of life of our patients from COPD to Crohns disease and beyond.

Together, RMS and the Lung Institute will offer patients access to better care with a staff dedicated to one goal: Improving quality of life in patients. Financial terms of the agreement were not disclosed. RMS has facilities in Tampa and Lima, Peru.

About Regenerative Medicine Solutions Regenerative Medicine Solutions (RMS) is a leading global provider of innovative regenerative technologies in order to treat an array of debilitating medical conditions. Committed to an individualized patient-centric approach, RMS consistently provides the highest quality of care while producing positive outcomes. By applying modern-day best practices to the growing field of regenerative medicine, RMS is changing lives. For more information, visit our website at myregenmed.com, like us on Facebook, or follow us on Twitter or call us today at 1-855-469-5864.

About Lung Institute Located in Tampa, Florida, the Lung Institute is changing the lives of hundreds of people across the world through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, visit our website at LungInstitute.com, like us on Facebook, follow us on Twitter or call us today at 1-855-4MY-LUNG.

Read this article:
Regenerative Medicine Solutions Acquires Advanced Healthcare Partners

Raleigh, NC (PRWEB) June 26, 2014

The AKC Canine Health Foundation (CHF) is pleased to announce the funding of a landmark clinical trial to establish the evidence-based use of regenerative medicine to treat tendon injury in dogs.

Funded as part of CHFs Canine Athlete Initiative which seeks to fund research and provide education for dog owners in the rapidly expanding field of canine sports, this newly funded collaborative grant will inform the veterinary community in the use of safe and effective regenerative medicine techniques.

According to Dr. Shila Nordone, CHF Chief Scientific Officer, Regenerative medicine is a rapidly developing field with the potential to transform the treatment of canine and possibly human disease. Nordone goes on to say, Because current regenerative medicine products and techniques vary widely and success stories are anecdotal at best, CHF is committed to funding independent studies that support the evidence-based practice of regenerative medicine.

Principal Investigators Dr. Jennifer Barrett, MS, PhD, DVM, DACVS, DACVSMR; Dr. Sherman Canapp, DVM, MS, CCRT, DACVS, DACVSMR; and Dr. Victor M. Ibrahim, MD, FAAPMR, will conduct the first blinded, placebo-controlled clinical trial evaluating the effectiveness of platelet-rich plasma and stem cells on the most common sporting injury in dogs: supraspinatus tendonopathy, a shoulder injury that is similar to rotator cuff injury in humans.

In dogs, tendon injuries often progress undiagnosed and result in chronic lameness and pain. If left untreated, scar tissue may form, reducing the function of the joint and surrounding muscle tissue. Through this grant, a collaborative group of veterinary sports medicine specialists across multiple disciplines will determine if regenerative mediScine therapies promote healing through tissue regeneration and reduced scarring.

As dogs are living longer and participating in more sporting events, CHF is committed to being on the leading-edge of novel therapies that will help all dogs stay Fit For Sport, Fit For Life.

CHF is a non-profit organization dedicated to funding research to prevent, treat, and cure canine disease. Visit CHF online at http://www.akcchf.org for more information about the Foundation. Like CHF on Facebook, follow CHF on Twitter @CanineHealthFnd, or connect with CHF on LinkedIn.

# # #

About CHF:

Visit link:
AKC Canine Health Foundation Funds Landmark Clinical Trial on Regenerative Medicine Treatment for Dogs

What cantodaysgenerationhope for fromregenerativemedicine?

Its a frontier for business, the medical profession and society. Regenerative medicine aims to shift the focus from palliative care to the development of treatments that address diabetes, Parkinsons disease, stroke and heart disease. The hope is that well live longer, healthier lives and have greater independence in old age, thereby reducing the burden on healthcare systems. Given global population demographics, this is essential: according to the World Health Organisation by 2050 there will two billion people aged 60 years and over.

Regenerative medicine already has a rich history of achievement, as illustrated in the timeline. Today, researchers and doctors are making inroads via the use of cell therapies, tissue scaffolds and growth factors; and new technologies, such as 4D bioprinting, all promising to dramatically increase the speed of progress. A number of companies present at BIO 2014, including AntiCancer Inc., RegenLab, Sanford Health, Merck, Lilly and Janssen Pharmaceutical Companies of Johnson & Johnson are pioneering regenerative medicine projects.

To get a better grasp of the achievements, challenges and potential of regenerative medicine, we talked to four of the worlds leading experts in the field. Heres what they told us.

Aubrey de Grey is the biomedical gerontologist who founded SENS (Strategies for Engineered Negligible Senescence) Research Foundation. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.

What do you think are the greatest achievements in regenerative medicine so far?

I think it would be difficult to argue against two breakthroughs published in 2006 and 2008 respectively: induced pluripotent stem cells (Shinya Yamanaka) and decellularisation of organs (Doris Taylor). Both these techniques proved to be quite easy to reproduce in other laboratories, so their potential is moving towards the clinic far more quickly than usual.

What are the biggest challenges in this research and development space? It remains highly challenging to generate sufficiently pure stem cells of a desired type to ensure safety and efficacy. Also, while the decellularisation approach is a great breakthrough, we still need to get better at reseeding a scaffold with desired cells. As a solution to the vascularisation issue that has stalled solid-organ tissue engineering for so long, a promising alternative to decellularisation is organ printing, but it still faces daunting obstacles in terms of creating sufficiently tough blood vessels.

Where do you think the field will be in 10 years? I think regenerative medicine will be at the heart of medicine for the elderly by 2024, having reached a level of sophistication that allows the genuine cure of relatively simple age-related conditions such as Parkinsons Disease and the alleviation of a wide range of aspects of age-related ill-health.

See the original post here:
My Regeneration

Institute for Stem Cell and Regenerative Medicine at the University of Washington
Meet the folks behind the impressive discoveries and science occurring at UW Medicine #39;s South Lake Union Research complex. http://depts.washington.edu/iscrm/ http://www.uwmedicine.org http://depts.washing...

By: UWMedicineHealth

See the original post:
Institute for Stem Cell and Regenerative Medicine at the University of Washington - Video

Poway, CA (PRWEB) June 11, 2014

Founder and CEO of Vet-Stem, Inc., a leading Regenerative Veterinary Medicine company, Robert J. Harman, DVM presented at The Orthobiologic Institute (TOBI) PRP (Platelet Rich Plasma) and Regenerative Medicine Symposium June 6-7 in Las Vegas. The Symposium with Cadaver Lab boasts over 20 lectures from world-renowned experts in biologics.

Dr. Harman will be presenting on The Future of Biologics: Signposts from Equine Therapies, drawing on a decade of experience developing new products in the Regenerative Veterinary Medicine industry with Vet-Stem, and overseeing the completion of more than 1,000 contract research projects for the development of veterinary and human biotechnology products over his entire career. More recently Dr. Harman brought to the veterinary market Vet-Stems GenesisCS-2 PRP Kit. The kit is optimized for equine use, to provide a rich source of autologous growth factors and bio-scaffolding for use in an area of acute injury, mainly in tendons and ligaments.

Many human medicine practices of the future are first proven in veterinary medicine, with typical use of products and validation from animal data being the flagship for human approvals and protocols. Dr. Harmans company is leading its industry in science-based literature including peer-reviewed studies to prove efficacy and to identify best practices in Regenerative Veterinary Medicine.

TOBI was established to share best practices in cutting-edge PRP and regenerative medicine therapies, drawing global opportunities for physicians to connect within the rapidly growing field. It strives to raise the standards of education and training with intensive hands-on programs and world-class informational curriculums. Courses are intended for Physiatrists, Sports Medicine Physicians, Orthopedists, Rheumatologists and more; addressing areas of the body including shoulder, elbow, wrist/hand, hip, knee, ankle/foot.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Read this article:
Robert J. Harman, DVM, CEO and Founder of Vet-Stem, Inc. Presents at PRP and Regenerative Medicine Symposium of The ...

10.06.2014 - (idw) Fraunhofer-Institut fr Grenzflchen- und Bioverfahrenstechnik IGB

For her outstanding research in tissue engineering and regenerative medicine Fraunhofer scientist Prof. Dr. Katja Schenke-Layland has been distinguished with the 2014 Young Scientist Award of the Tissue Engineering & Regenerative Medicine International Society European Chapter (TERMIS-EU). The Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and the University Women's Hospital Tbingen biologist Katja Schenke-Layland received the Young Scientist Award of the Tissue Engineering & Regenerative Medicine International Society European Chapter (TERMIS-EU) on 10 June in Genoa, Italy, during the annual conference of the TERMIS-EU. With the prize, the TERMIS-EU acknowledges outstanding achievements of young, promising scientists in the field of tissue engineering and regenerative medicine. Basis for the award were her high quality publications in highly cited journals, leadership activities, grant income from major funding bodies and external recognition amongst the wider international TERM community. Katja Schenke-Layland has published 73 articles, 23 as first and 27 as senior author, with an h-index of 23 and over 1600 total citations.

Scientific career in cardiovascular tissue engineering

Since the beginning of her Ph.D. studies, Katja Schenke-Layland has been developing regenerative strategies to restore the functionality of damaged hearts. She has identified extracellular proteins that are important for heart valve and cardiac muscle development and designed biological approach to incorporate this knowledge into potential therapies. A focus of her current work has been the production of synthetic, biocompatible carrier material to mimic the biological structure of the developing human heart. The scaffolds are designed to attract endothelial progenitor cells circulating in the blood that can repopulate the valve. These cells will begin to modify and rebuild the synthetic scaffolds while in the body, allowing for the potential growth of the scaffolds. The ambitious goal is to further develop this support material to a cell-free off-the-shelf heart valve.

History of a research talent

Katja Schenke-Layland studied biology, sociology and psychology at the University of Jena. She graduated in 2004 with a doctorate in biology, which focused on heart valve tissue engineering and non-invasive tissue analysis. Schenke-Layland was awarded the Family Klee award from the German Society for Biomedical Engineering. She then moved to the United States where she conducted research at the Saban Research Institute of Children's Hospital Los Angeles and the University of California in Los Angeles (UCLA), which was funded by a fellowship from the German Research Foundation (DFG). In 2010, she was promoted to Assistant Research Professor at UCLA and received the award for Morphological Sciences from the American Association of Anatomists for her work in cardiac stem cell research.

Schenke-Layland returned to Germany in 2010 after being awarded the Attract-program grant of the Fraunhofer-Gesellschaft to continue her work in cardiovascular tissue engineering. In 2011, she was appointed Professor for biomaterials in cardiovascular regenerative medicine" at the University Hospital Tbingen, where she leads a research group in parallel with her position at Fraunhofer IGB. Since mid-2013, she co-heads the Department of Cell and Tissue Engineering at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart and has held the appointment of Adjunct Associate Professor at UCLA. Weitere Informationen:http://www.igb.fraunhofer.de/en/press-media/press-releases/2014/katja-schenke-la...

Link:
Katja Schenke-Layland distinguished with TERMIS-EU 2014 Young Scientist Award

Rheumatoid arthritis | umbilical cord stem cells for ra
http://www.arthritistreatmentcenter.com Another type of stem cell that could hold potential for rheumatoid arthritis treatment... next Umbilical cord stem cells may be useful in the treatment...

By: Nathan Wei

Read more from the original source:
Rheumatoid arthritis | umbilical cord stem cells for ra - Video

Through regenerative medicine, your ADRCs can rebuild damaged muscle tissue

In the country, there is a facility identified as the first medical center in South East Asia to offer the most advanced regenerative medical procedures. It utilizes state-of-the-art processing, delivery, and preservation of medical-grade Adipose-Derived Regenerative Cells (ADRCs). Located at Zuellig Bldg. Makati Avenue cor. Paseo De Roxas, Makati City, EA Regenerative Medicine Center of Excellence follows the most stringent clinical protocols, registries and standards of operations.

The center makes use of the Celution System from Cytori Therapeutics USA. Their process involves the extraction of unwanted fats derived from the patients own body and isolating the healthy therapeutic cells which can then be administered for the treatment of a whole range of age-related conditions like cardiovascular diseases, orthopedics, muscle, ligament and soft tissue injuries, gastrointestinal disorders, pain management, and procedures for plastic and reconstructive surgery that ensure the safest, most natural, and efficient healing process available to modern health science.

SO HOW DOES IT WORK?

There are stem cells throughout the human body, but theyre rare and difficult to access. The problem facing companies interested in treatment models is this: in order to get therapeutic numbers, you have to grow the stem cells in cultures.

This process fundamentally transforms the cells, based on their time in culture. Under existing FDA regulations, it also effectively makes any treatment derived from a drug, with all the development costs, regulatory hurdles and expenses to get over before having a product to bring to patients.

Theres really not a tissue in the body where, with impunity and effectively no risk, you can take a liters worth from anybody, says David Oxley, Cytori vice president.

But there is your body fatthe thing most of us hate wearing around our waistlines the most.

Fat tissue is one of the sources of therapeutic levels of stem cells. Theres no comparison, says Dr. Eder Garcia Dizon, managing director of EA Regenerative Medicine Center of Excellence. Even bone marrow and cord blood as source pales in comparison from a volume and number of cells perspective.

The Celution system was devised by Cytori to get those cells from the patients fat tissue to their targeted area of need as quickly and efficiently as possible.

Read the original here:
Your fat can heal your heart